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ABSTRACT 
Overweight and obesity are rapidly increasing in prevalence due to adoption of the westernized life style in Korea. 
Obesity is strongly associated with the development of cardiovascular risk factors such as diabetes, hypertension, 
and dyslipidemia. In addition, accumulating evidence suggests that obesity per se has a direct effect on cardiac func-
tional and structural changes that may not be the result of atherosclerosis. In this review, we focus on the view 
that obesity can influence on the structural and functional changes of the heart, drawing evidence from human 
and animal studies. We also review influencing factors such as physical, neurohormonal, and metabolic altera-
tions that are associated with changes of the heart in obesity. (Korean Circ J 2010;40:55-61) 
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Introduction 
 
The prevalence of obesity is increasing due to the 
increasing adoption of westernized life styles in Korea. 
Obesity is defined by body mass index (BMI), which is 
classified as underweight (<20 kg/m
2), normal (20-24.9 
kg/m
2), overweight (25-29.9 kg/m
2), and obese (≥30 kg/ 
m
2). Korean National Health Examination and Nutri-
tion Survey data in 2001 estimated that 3.0% of Korean 
adults were obese and 29.5% were overweight.
1) The pre-
valence of overweight Korean children and adolescents 
doubled from 5.4% in 1998 to 11.4% in 2001.
2) Increas-
ing degrees of obesity are closely correlated with the 
increasing rates of cardiovascular disease.
3) Furthermore, 
a large body of evidence strongly supports the view that 
obesity itself is associated with preclinical structural and 
functional changes in the heart, which prelude heart 
failure.
4) In this review, we discuss the changes of car-
diac structure and function in obesity and focus on the 
current evidence regarding the causative role of obesity 
in cardiac changes.   
 
Structural Changes in the Heart 
in Obesity 
 
Animal studies regarding structural changes of he-
art in obesity 
Two types of animal models are used in obesity stu-
dies: genetic mutant models and high fat diet-induced 
obesity model. Genetic mutant mice models, such as 
ob/ob and db/db, present severe types of obesity. The 
ob/ob and db/db mice models become progressively 
obese, left ventricular (LV) hypertrophy develops, and 
LV mass increases. Interestingly, leptin infusion to these 
mice leads to decreased myocardial wall thickness.
5) LV 
hypertrophy is a common cardiac phenotype in the res-
ponse of genetic mutant mice to obesity. Use of high 
fat diet mice has demonstrated that increased non-es-
terified fatty acid (NEFA) contents, which diminish the 
rate of glucose metabolism and increase oxygen con-
sumption, result in reduced ability to recover from a 
workload.
6) Furthermore, high fat diet mice also dis-
play elevated blood pressure and impaired insulin re-
ceptor activation.
7) All of these factors contribute to 
the development of cardiac hypertrophy and LV dys-
function in high fat diet mice.
7)  
Results from the two animal models indicate that 
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obesity may result in cardiac hypertrophy due to insulin 
resistance (IR), metabolism alteration such as leptin de-
ficiency, or leptin resistance and elevated blood pressure. 
 
Obesity and left ventricular hypertrophy   
in human 
Obesity is an independent factor for LV hypertro-
phy.
8-11) Obesity itself may have hemodynamic effects 
that produce an increase in the total blood volume 
and cardiac output due to the high metabolic activity 
of excessive fat. In moderate to severe obesity, these 
increases may lead to LV dilation, increased LV wall st-
ress, and compensatory (eccentric) LV hypertrophy.
8)9) 
Despite this logical explanation, recent studies have 
shown that concentric LV hypertrophy is a predomi-
nant form in obese subjects.
10)11) Besides hemodynamic 
factors, hyperinsulinemia due to IR, which stimulates 
insulin like growth factor-1 (IGF-1) receptors, is also 
involved in the pathogenesis of LV hypertrophy.
12) IGF-1 
enhances anabolic effects on the myocardium, and fa-
cilitates increased myocardial mass and concentric hy-
pertrophy. Systolic hypertension is traditionally known 
as a major contributor to LV hypertrophy rather than 
obesity. However, in the Framingham heart study, the 
investigators found independent influences of BMI 
and blood pressure on LV mass index.
13) Therefore, the 
effects of obesity and blood pressure were additive on 
LV changes. However, opinion is divided concerning 
which components are the stronger predictor of LV hy-
pertrophy. Obesity was the strongest clinical predictor 
for LV hypertrophy in several studies,
12)14) while another 
study showed that BMI and hypertension affect LV hy-
pertrophy similarly.
15)  
In summary, obesity induces LV hypertrophy via he-
modynamic changes caused by hyperinsulinemia, in-
creased IGF-1 expression, and volume overload, which 
are similar to the effect caused by hypertension. 
 
Obesity and cardiac adipocytes in human 
Epicardial fat mass, as determined by echocardiogra-
phic and magnetic resonance imaging studies, may re-
flect intra-abdominal visceral fat. Therefore, epicardial 
fat mass could serve as a marker of visceral adiposity.
16) 
The relationship between local adipose tissue in heart 
and cardiac geometry has recently been studied. Incre-
ased epicardial fat mass and fatty infiltration of myo-
cardium contributed to the increased cardiac mass.
17) Al-
though epicardial fat is normally accounted for about 
20% of the total ventricular mass, total epicardial fat wei-
ghts are significantly greater in hypertrophic heart.
18) 
The causal effect of epicardial adipose tissue on car-
diac remodeling remains unsolved. However, epicar-
dial adipose tissue serves as an endocrine organ, which 
releases monocyte chemotactic protein-1, interleukin-1β, 
interleukin-6 and tumor necrosis factor-alpha. These 
adipokines may be important factors in cardiac remo-
deling or hypertrophy in obese subjects.
19) 
 
Obesity and left atrial enlargement in human 
Left atrial (LA) size and LA volume is increased in 
the setting of obesity compared with non-obese indivi-
duals.
20) The possible mechanisms of increased LA size 
and volume in obesity are similar to those of LV hyper-
trophy in obesity; increased BMI leads to volume over-
load,
21) which causes diastolic abnormality of LV filling 
defect. Diastolic dysfunction can contribute to LA en-
largement or remodeling.
22) In the Framingham heart 
study, obesity was found to be a strong risk factor for 
development of atrial fibrillation even after accounting 
for concomitant conditions such as hypertension, dia-
betes mellitus, and myocardial infaction.
23) In the cli-
nical setting, dilated LA size in the absence of organic 
heart disease or atrial fibrillation is considered to be a 
risk factor for developing atrial fibrillation and long-
term cardiovascular events.
24)  
 
Functional Changes of the Heart 
in Obesity 
 
Changes of left ventricular systolic function   
The effects of obesity on LV systolic function are con-
troversial. Several studies reported that LV systolic func-
tion is normal or increased in obesity.
8)9)25) However, 
some evidence from non-invasive or invasive techniques 
suggests that obesity causes a subclinical contractility 
abnormality.
11)26)27) Obesity-induced myocardial dysfunc-
tion can be explained by the derangement of myocar-
dial metabolism. In animal models, IR in obesity cause 
alterations in myocardial fatty acid metabolism and ef-
ficiency (cardiac work/myocardial oxygen consumption) 
that occur early in the cascade of events, leading to im-
paired LV contractility.
28) In human studies, obesity is 
a significant predictor of increased myocardial oxygen 
consumption and decreased efficiency, and IR is a ro-
bust predictor of fatty acid uptake, utilization, and oxi-
dation. These metabolic changes may play a role in the 
pathogenesis of decreased cardiac performance in obe-
sity.
29) Collectively, obesity might be a strong factor that 
can induce LV systolic dysfunction and eventually cause 
heart failure independent to coronary artery disease or 
other morbidities.   
 
Changes of left ventricular diastolic function   
Echocardiography studies conducted with obese ani-
mals and human have provided inconsistent results 
about E-wave velocity, deceleration time, A-wave velo-
city.
11)30) Prolongation of the isovolumic relaxation time 
may be the most consistent diastolic abnormality in 
obesity.
31)32) In uncomplicated obese subjects, diastolic 
dysfunction is caused by hemodynamic and metabolic  
 
Joong Kyung Sung, et al.·57 
factors. Hemodynamic changes cause diastolic dysfunc-
tion in obese subjects through LV hypertrophy.
33) Meta-
bolic factors will be discussed later chapter. Other po-
tential mediators include hormones and cytokines re-
leased in association with obesity. Changes of adipo-
kine concentration in serum, such as leptin and adipo-
nectin, are observed in obese subjects, which may also 
be partly responsible for the LV diastolic dysfunction. 
Studies with ob/ob mice (which are deficient in leptin) 
have demonstrated diastolic dysfunction by the changes 
of myocardial fatty acid and glucose metabolsim.
28)34) Si-
milarly, leptin resistance and hyperleptinemia are ob-
served in obese subjects, which may lead to diastolic 
dysfunction. Circulating total and high-molecular-weight 
adiponectin are negatively correlated with LV wall thick-
ness and diastolic dysfunction independent of age and 
metabolic factors.
35) In the Otsuka Long-Evans Toku-
shima Fatty rat model of pre-diabetes, pre-diabetic con-
ditions cause an accumulation of myocardial collagen, 
leading to interstitial and perivascular fibrosis, which 
correlates with LV early diastolic dysfunction.
36)  
Collectively, the evidence indicates that the precli-
nical diastolic dysfunction of obesity is related to hemo-
dynamic alteration, various adipokines, and myocardial 
collagen accumulation.   
 
Several Mechanisms that Influence 
the Structure and Function 
of the Obese Heart 
 
Hemodynamic changes 
Obesity causes an increase in total blood volume and 
cardiac output.
37) In addition, high blood pressure is 
commonly found in obesity, with an estimated preval-
ence of up to 60%.
38) These hemodynamic factors af-
fect the cardiac geometry, especially LV hypertrophy.   
 
Sleep apnea in obesity 
Obstructive sleep apnea (OSA) is a very common 
abnormality in obese subjects. The Wisconsin Sleep 
Cohort Study demonstrated that the risk of develop-
ment of hypertension in OSA patients is three times 
higher than non-OSA subjects.
39) Likewise, OSA patients 
demonstrated not only day-time hypertension but night-
time hypertension or non-dipper pattern.
39) Repetitive 
episodes of airway obstruction cause hypoxemia and ch-
anges of intra-thoracic pressure, which in turn causes 
sympathetic overactivity. Furthermore, chronic hypoxe-
mia causes injury to myocytes and cardiac extracellular 
matrix. All of these factors-hypertension, sympathetic 
overactivity, hypoxemia-lead to ventricular remodeling.
40) 
One study reported that 88% of OSA patients have LV 
hypertrophy and 64% of those have LA enlargement.
41) 
The authors also demonstrated that the use of conti-
nuous positive airway pressure for 6 months could re-
duce LV hypertrophy.
41) All these findings suggest that 
the severity of nocturnal hypoxemia could be impor-
tant in the development of LV hypertrophy in obese 
subjects with OSA.   
 
Changes of cardiac metabolisms, mitochondrial 
dysfunction and oxidative stress 
Energy sources of myocardial metabolism are differ-
ent from diabetes compared to normal glucose tolerance 
subjects. In the setting of diabetes or IR, myocardium 
utilizes much more free-fatty acid and less glucose, 
which occurs even in the early course of obesity.
42) Long-
standing caloric excess or obesity activates peroxisome 
proliferator-activated receptor-α/peroxisome prolife-
rator-activated receptor-γ coactivator signaling, which 
increases the expression of genes involved in fatty acid 
oxidation and fatty acid transporters such as FATP1 
and CD36.
43)44) In human, obesity is also associated 
with increased rates of fatty acid oxidation, increased 
myocardial oxygen consumption, and reduced cardiac 
performance proportionate to the degree of IR and obe-
sity.
29) Indeed, normalization of cardiac metabolism by 
overexpression of a human GLUT4 transgene in db/db 
mice reverses cardiac dysfunction, which suggests that 
altered myocardial metabolism contributes to contrac-
tile dysfunction in this model.
45) It has been demonst-
rated that mitochondrial oxygen consumption rate and 
adenosine triphosphate (ATP) generation capacity are 
reduced in ob/ob mice, and that the protein levels of 
mitochondrial complexes I, III, V for the oxidative ph-
osphorylation are significantly reduced in db/db mice.
46) 
Because of mitochondrial response in obesity or dia-
betes, the ratio of ATP generation and oxygen consump-
tion is reduced (mitochondrial uncoupling), which is be-
lieved to be a significant factor for declination of cardiac 
function.
46) Mitochondria also represent a major source 
of superoxide production. In db/db mice, mitochondrial 
reactive oxygen species generation increases, which can 
damage myocardial cells.
46) 
In summary, cardiac metabolic changes, mitochondrial 
dysfunction, and oxidative stress can cause declination 
of cardiac function in obese subjects.   
 
Insulin resistance 
IR represents problems of insulin receptor, insulin 
signaling, and genetics. Among these problems, insu-
lin signaling impairment could be the key factor for IR. 
Impaired insulin-mediated activation of intracellular 
signaling has been described in ob/ob mice.
42) In the 
animal models, obesity and IR can increase myocardial 
fatty acid uptake, which causes myocardial fatty acid 
oxidation and myocardial oxygen consumption. Persist-
ence of this metabolic change causes an imbalance of 
fatty acid uptake and fatty acid oxidation, leading to 
accumulation of fatty acid intermediates and ceramide  
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production, which impairs myocardial function and 
increases apoptosis of myocardocytes.
47)48) This pheno-
menon has also been demonstrated in human.
29) How-
ever, in Zucker fatty rats treated with the insulin sen-
sitizer thiazolinedione (TZD), myocardial glucose con-
sumption was increased, fatty acid oxidation was dimi-
nished, and myocardial injury was reduced.
49) In ad-
dition, hyperinsulinemia stimulates IGF-1 receptors, 
which is likely responsible in the pathogenesis of myo-
cardial hypertrophy.
12) 
 
Neurohormonal activations   
In general, obese subjects have activated sympathetic 
tone. This leads to concentric LV hypertrophy due to 
elevated afterload and increased cardiac contractility. 
Additionally, catecholamine directly affects the myo-
cardium without hemodynamic influence. The renin-
angiotensin system also affects the heart via hemodyna-
mic effects or direct signaling in obesity.
50) Angioten-
sinogen secretion and its messenger ribonucleic acid 
(mRNA) have been detected in fa/fa rat adipocytes 
and in human.
51) Angiotensin is thought to be a con-
tributor to the sympathoexcitation, therefore the ren-
nin-angiotensin system could increase central sympa-
thetic activation and have a role as an additive effect to 
blood pressure elevation and cardiac remodeling in 
obese subjects.
52)  
 
Changes of extracellular matrix and fibrosis 
The compositional changes of the extracellular ma-
trix is an important contributor in cardiac remodel-
ing.
53) Serum levels of cardiac collagen synthesis have 
been significantly associated with IR in normotensive 
and non-diabetic obese subjects.
54) In another study 
using a rabbit model of obesity, a high-fat diet caused 
fibrosis in coronary vessels as well as the accumulation 
of collagen in the cardiac interstitium.
55)  
Adipokines such as adiponectin or leptin play an 
important role in the extracellular matrix changes of 
the heart. Leptin is an adipokine that is produced in 
the obese gene (ob) located in adipocytes.
56) In one st-
udy, leptin increased matrix metalloproteinase-2 (MMP-
2) secretion and its mRNA expression, and attenuated 
collagen I mRNA synthesis and increased collagen III 
and IV, but did not change total collagen synthesis in 
human pediatric ventricular myocytes.
57) In a diet-in-
duced obesity murine model, elevated leptin level was 
detected after 20 weeks of a high fat diet, and this lep-
tin level was correlated with reduced ventricular shor-
tening and increased LV posterior wall thickness.
58) In 
the coronary ligation model, procollagen I and III levels 
were elevated after 7 days postinfarction. Furthermore 
when the neutralizing leptin antibody was injected, en-
hanced collagen was attenuated.
59) 
Adiponectin is considered a cardioprotective adipo-
kine. A recent study suggested that adiponectin level 
showed positive correlation with tissue inhibitor of 
metalloproteinase (TIMP), which is considered to exert 
an antifibrotic effect.
60) The adiponetin levels are decreas-
ed in the obese or IR subjects; the cardioprotective ef-
fect of adiponectin, especially its antifibrotic effect, is di-
minished in obese subjects. 
In obese subjects, adipocytokines such as catechola-
mine, rennin-angiotensin-aldosterone system, tumor ne-
crosis factor-alpha, C-reactive protein, leptin, and adi-
ponectin influence to MMP activity, TIMP expression, 
and collagen synthesis, which ultimately leads to car-
diac remodeling.
53)  
 
Apoptosis of cardiomyocytes 
The evidence of cardiac apoptosis in the genesis of 
heart failure has surged over the last decade. Apoptotic 
cardiomyocyte death has been proven from biopsies of 
dilated cardiomyopathy and end stage heart failure.
61) 
Besides apoptotic cell death, activation of several pro-
teases in the apoptotic cascade can cleave contractile 
proteins including actin, myosin, and troponins.
62) Th-
ere are numerous causes of apoptosis. Apoptosis appears 
to be ischemia or ischemia-reperfusion driven at the 
site of infarct and at sites remote from the ischemic area 
through neurohormonal effects. Myocardial stretch, 
wall stress, cytokines, and neurohormones such as nor-
epinephrine and angiotensin II, which are commonly 
produced as a part of peripheral neurohormonal rear-
rangements after an acute myocardial infarction, have 
been demonstrated to enhance apoptosis.
63)64)  
Studies for obesity associated cardiac apoptosis are 
lacking. Use of the Zucker fatty rat model has shown 
that cardiac contractility is reduced with increased car-
diac cell apoptosis; however, when the rats were treated 
with TZD, cardiac cell apoptosis was decreased.
48) An-
other study involving a high fat diet induced IR rat 
model did not reveal a significant difference in apo-
ptosis compared with control group, despite impaired 
cardiac function.
65) Therefore, it is necessary to study the 
relationship between obesity, cardiac cell apoptosis, and 
impairment of cardiac function.   
 
Therapeutic Implications 
 
Weight reduction improves systolic blood pressure, 
IR, sleep apnea, and hyperlipidemia. Weight reduction 
also has beneficial effects on cardiac structure and func-
tion such as reduction of LV diameter, LV wall thick-
ness, LV mass, and LA dimension.
66) However, removal 
of subcutaneous fat by liposuction does not produce a 
beneficial effect on metabolic changes, so it has little 
effect on the cardiovascular system.
67) Pharmacologi-
cal-mediated weight reduction is recommended for pa-
tients in whom lifestyle modification has failed. Ori- 
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stat, which is a gastrointestinal lipase inhibitor, can 
reduce weight by about 3 kg and decreases progression 
to diabetes in high risk patients.
68) Sibutramine, a mo-
noamine reuptake inhibitor, can reduce weight by about 
4-5 kg and improves serum lipid levels and insulin sen-
sitivity,
69) but it increases heart rate and blood pressure. 
Rimonabant, an endocannabinoid receptor blocker, re-
duces weight by 4-5 kg, decreases waist circumference, 
and improves serum high density lipoprotein choles-
terol and triglyceride levels.
70) However, there are no de-
finitive data for the effect on cardiac structure and func-
tion in use of these medications.
71) Therefore, weight re-
duction by diet and exercise is still the most important 
means to correct the functional and structural deteri-
orations that occur in the heart in obese individuals. 
 
Conclusions 
 
Obesity is a causative factor for development of pre-
clinical changes of the heart. In obese subjects, initially 
volume overload develops, which leads to increased 
cardiac output and hypertension. Second, sympathetic 
and rennin-angiotensin-aldosterone system activity is 
increased, which causes hypertension. Third, hyperin-
sulinemia (IR) increases advanced glycation end-pro-
ducts and IGF-1 production and facilitates fatty acid 
uptake, which leads to lipotoxic cell damage. Fourth, vis-
ceral adipose tissue affects oxidative stress and is relat-
ed with decreased leptin level or leptin resistance and 
decreased adiponectin level; these changes affect cellu-
lar changes and metabolic alteration. Fifth, cellular ch-
anges are produced by neurohormonal and metabolic 
factors, oxidative stress, and adipokines, which leads to 
extracellular fibrosis and apoptosis. All these descrip-
tive factors eventually lead to structural and functional 
changes of the heart in obesity (Fig. 1). Therapeutically, 
life-style associated weight reduction may be more im-
portant than any other molecular- or pathway-targeted 
therapy. 
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